{"id":"peg-interferon-alpha-2a-and-ribavin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Anemia"},{"rate":"5-15","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"20-40","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peg-interferon alpha-2a is a pegylated form of interferon-alpha that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory responses including activation of natural killer cells and T cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces hepatitis C virus replication. The combination has synergistic antiviral activity against HCV.","oneSentence":"Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:09.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C infection"}]},"trialDetails":[{"nctId":"NCT00485342","phase":"PHASE3","title":"RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2006-04","conditions":"Chronic Hepatitis C","enrollment":236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Peg-interferon alpha 2a and ribavin","genericName":"Peg-interferon alpha 2a and ribavin","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication. Used for Chronic hepatitis C infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}